Shares of Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) have received an average rating of “Buy” from the six analysts that are covering the firm, MarketBeat Ratings reports. Three research analysts have rated the stock with a hold rating and three have issued a buy rating on the company. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $11.75.

Several research analysts recently weighed in on TTPH shares. BMO Capital Markets restated a “buy” rating and set a $12.00 target price on shares of Tetraphase Pharmaceuticals in a research note on Friday, May 5th. Zacks Investment Research upgraded Tetraphase Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Thursday, July 6th. HC Wainwright started coverage on Tetraphase Pharmaceuticals in a research note on Tuesday, July 11th. They set a “buy” rating and a $15.00 target price on the stock. Stifel Nicolaus upgraded Tetraphase Pharmaceuticals from a “hold” rating to a “buy” rating and boosted their target price for the stock from $8.00 to $15.00 in a research note on Wednesday. Finally, Needham & Company LLC restated a “hold” rating on shares of Tetraphase Pharmaceuticals in a research note on Thursday.

Tetraphase Pharmaceuticals (NASDAQ:TTPH) traded down 11.68% during midday trading on Thursday, hitting $6.96. The stock had a trading volume of 3,876,478 shares. The stock’s market cap is $264.17 million. The company’s 50 day moving average price is $7.48 and its 200-day moving average price is $6.84. Tetraphase Pharmaceuticals has a 52-week low of $3.11 and a 52-week high of $9.93.

Tetraphase Pharmaceuticals (NASDAQ:TTPH) last announced its quarterly earnings results on Tuesday, May 2nd. The biopharmaceutical company reported ($0.79) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.60) by $0.19. Tetraphase Pharmaceuticals had a negative net margin of 1,932.24% and a negative return on equity of 60.55%. The company had revenue of $1.48 million during the quarter, compared to analysts’ expectations of $1.46 million. During the same quarter in the prior year, the business posted ($0.46) earnings per share. The company’s revenue was down 24.5% compared to the same quarter last year. Analysts forecast that Tetraphase Pharmaceuticals will post ($2.66) EPS for the current fiscal year.

A number of institutional investors have recently added to or reduced their stakes in the company. UBS Group AG raised its stake in Tetraphase Pharmaceuticals by 2.3% in the first quarter. UBS Group AG now owns 17,269 shares of the biopharmaceutical company’s stock valued at $159,000 after buying an additional 387 shares during the period. Teza Capital Management LLC raised its stake in Tetraphase Pharmaceuticals by 8.9% in the first quarter. Teza Capital Management LLC now owns 15,650 shares of the biopharmaceutical company’s stock valued at $144,000 after buying an additional 1,281 shares during the period. American International Group Inc. raised its stake in Tetraphase Pharmaceuticals by 7.1% in the first quarter. American International Group Inc. now owns 22,390 shares of the biopharmaceutical company’s stock valued at $206,000 after buying an additional 1,486 shares during the period. Citadel Advisors LLC raised its stake in Tetraphase Pharmaceuticals by 18.6% in the first quarter. Citadel Advisors LLC now owns 15,924 shares of the biopharmaceutical company’s stock valued at $146,000 after buying an additional 2,496 shares during the period. Finally, Bank of New York Mellon Corp raised its stake in Tetraphase Pharmaceuticals by 3.4% in the first quarter. Bank of New York Mellon Corp now owns 187,897 shares of the biopharmaceutical company’s stock valued at $1,726,000 after buying an additional 6,114 shares during the period. 46.24% of the stock is owned by institutional investors.

WARNING: This article was posted by American Banking News and is the sole property of of American Banking News. If you are viewing this article on another website, it was copied illegally and reposted in violation of U.S. & international trademark and copyright legislation. The original version of this article can be accessed at https://www.americanbankingnews.com/2017/07/27/tetraphase-pharmaceuticals-inc-ttph-given-consensus-recommendation-of-buy-by-brokerages.html.

Tetraphase Pharmaceuticals Company Profile

Tetraphase Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant gram-negative infections.

Analyst Recommendations for Tetraphase Pharmaceuticals (NASDAQ:TTPH)

Receive News & Ratings for Tetraphase Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.